Reports Q2 revenue $925M, consensus $937M. The company said, “”In the first half of the year we continued to make progress towards our strategic priorities as we strivetowards our goal of bringing our innovative therapies to additional patients in need. We further maximized thepotential of our commercialized medicines with an additional sBLA submission for EPKINLY and the launch of Tivdak (tisotumab vedotin) in Japan. We also accelerated the development of our late-stage pipeline through both encouraging data presentations and, for Rina-S, the announcement of additional planned Phase 3 clinical trials.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s EPCORE® FL-1 Trial Achieves Key Milestones in Follicular Lymphoma
- Genmab says Phase 3 EPCORE FL-1 trial met dual primary endpoints
- Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer?
- AbbVie and Genmab’s Promising Update on B-Cell Lymphoma Treatment Study
- AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment